Leukemia cells are sensitized to temozolomide, carmustine and melphalan by the inhibition of O6‑methylguanine‑DNA methyltransferase

Arai,Hajime; Yamauchi,Takahiro; Uzui,Kanako; Ueda,Takanori

doi:10.3892/ol.2015.3307

Leukemia cells are sensitized to temozolomide, carmustine and melphalan by the inhibition of O6‑methylguanine‑DNA methyltransferase

Authors:
- Hajime Arai
- Takahiro Yamauchi
- Kanako Uzui
- Takanori Ueda
View Affiliations

Affiliations: Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui 910‑1193, Japan
Published online on: June 2, 2015 https://doi.org/10.3892/ol.2015.3307
Pages: 845-849

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cytotoxicity of the monofunctional alkylator, temozolomide (TMZ), is known to be mediated by mismatch repair (MMR) triggered by O6‑alkylguanine. By contrast, the cytotoxicity of bifunctional alkylators, including carmustine (BCNU) and melphalan (MEL), depends on interstrand crosslinks formed through O6‑alkylguanine, which is repaired by nucleotide excision repair and recombination. O6‑alkylguanine is removed by O6‑methylguanine‑DNA methyltransferase (MGMT). The aim of the present study was to evaluate the cytotoxicity of TMZ, BCNU and MEL in two different leukemic cell lines (HL‑60 and MOLT‑4) in the context of DNA repair. The transcript levels of MGMT, ERCC1, hMLH1 and hMSH2 were determined using reverse transcription‑quantitative polymerase chain reaction. In addition, the proliferation was measured using the trypan blue exclusion assay. Drug sensitivity was found to vary between the two cell lines. Treatment of the cells with TMZ, BCNU or MEL in combination with O6‑benzylguanine, an MGMT inhibitor, was demonstrated to sensitize the two cell lines to these agents. However, the extent of sensitization was not found to be correlated with the expression levels of MGMT transcripts. Furthermore, the drug sensitivity was also not associated with the transcript levels of ERCC1, hMLH1 and hMSH2. Thus, leukemic cells were sensitized to alkylating agents by the inhibition of MGMT.

View Figures

View References

1	Tew KD, Colvin M and Chabner BA: Alkylating agentsCancer Chemotherapy and Biotherapy: Principles and Practice. Chabner BA and Longo DL: Lippincott-Raven Publishers; Philadelphia: pp. 297–317. 1996
2	Fu D, Calvo JA and Samson LD: Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 12:104–120. 2012.PubMed/NCBI
3	Geleziunas R, McQuillan A, Malapetsa A, Hutchinson M, Kopriva D, Wainberg MA, Hiscott J, Bramson J and Panasci L: Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst. 83:557–564. 1991. View Article : Google Scholar : PubMed/NCBI
4	Drabløs F, Feyzi E, Aas PA, Vaagbø CB, Kavli B, Bratlie MS, Peña-Diaz J, Otterlei M, Slupphaug G and Krokan HE: Alkylation damage in DNA and RNA - repair mechanisms and medical significance. DNA Repair (Amst). 3:1389–1407. 2004. View Article : Google Scholar : PubMed/NCBI
5	Wiencke JK and Wiemels J: Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Mutat Res. 339:91–119. 1995. View Article : Google Scholar : PubMed/NCBI
6	Povirk LF and Shuker DE: DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res. 318:205–226. 1994. View Article : Google Scholar : PubMed/NCBI
7	Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 6:2585–2597. 2000.PubMed/NCBI
8	Stupp R, Gander M, Leyvraz S and Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2:552–560. 2001. View Article : Google Scholar : PubMed/NCBI
9	Mason WP and Cairncross JG: Drug Insight: Temozolomide as a treatment for malignant glioma - impact of a recent trial. Nat Clin Pract Neurol. 1:88–95. 2005. View Article : Google Scholar : PubMed/NCBI
10	Fink D, Aebi S and Howell SB: The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 4:1–6. 1998.PubMed/NCBI
11	Fan CH, Liu WL, Cao H, Wen C, Chen L and Jiang G: O⁶-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis. 4:e8762013. View Article : Google Scholar : PubMed/NCBI
12	Fahrer J and Kaina B: O⁶-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer. Carcinogenesis. 34:2435–2442. 2013. View Article : Google Scholar : PubMed/NCBI
13	Chaney SG and Sancar A: DNA repair: Enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst. 88:1346–1360. 1996. View Article : Google Scholar : PubMed/NCBI
14	Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A and Aloyz R: Chlorambucil drug resistance in chronic lymphocytic leukemia: The emerging role of DNA repair. Clin Cancer Res. 7:454–461. 2001.PubMed/NCBI
15	Bowden NA: Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? Cancer Lett. 346:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
16	Martin SA, Lord CJ and Ashworth A: Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res. 16:5107–5113. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yamauchi T, Ogawa M and Ueda T: Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance. Mol Pharmacol. 74:82–91. 2008. View Article : Google Scholar : PubMed/NCBI
18	Yamamoto S, Yamauchi T, Kawai Y, Takemura H, Kishi S, Yoshida A, Urasaki Y, Iwasaki H and Ueda T: Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells. Int J Hematol. 85:108–115. 2007. View Article : Google Scholar : PubMed/NCBI
19	Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000. View Article : Google Scholar : PubMed/NCBI
20	Shrivastav N, Li D and Essigmann JM: Chemical biology of mutagenesis and DNA repair: Cellular responses to DNA alkylation. Carcinogenesis. 31:59–70. 2010. View Article : Google Scholar : PubMed/NCBI
21	Fiumicino S, Martinelli S, Colussi C, Aquilina G, Leonetti C, Crescenzi M and Bignami M: Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts. Int J Cancer. 85:590–596. 2000. View Article : Google Scholar : PubMed/NCBI
22	Loeber R, Michaelson E, Fang Q, Campbell C, Pegg AE and Tretyakova N: Cross-linking of the DNA repair protein O⁶-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards. Chem Res Toxicol. 21:787–795. 2008. View Article : Google Scholar : PubMed/NCBI
23	Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, et al: Phase II trial of temozolomide plus O⁶-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 27:1262–1267. 2009. View Article : Google Scholar : PubMed/NCBI
24	Adams DM, Zhou T, Berg SL, Bernstein M, Neville K and Blaney SMChildren's Oncology Group: Phase 1 trial of O⁶-benzylguanine and BCNU in children with CNS tumors: A Children's Oncology Group study. Pediatr Blood Cancer. 50:549–553. 2008. View Article : Google Scholar : PubMed/NCBI
25	Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
26	Balaña C, Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R, Sarries C, Mendez P, Sanchez JJ and Rosell R: O⁶-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res. 9:1461–1468. 2003.PubMed/NCBI
27	Aquilina G, Ceccotti S, Martinelli S, Hampson R and Bignami M: N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res. 58:135–141. 1998.PubMed/NCBI